Wave Life Sciences Ltd (WVE) concluded trading on Wednesday at a closing price of $10.02, with 3.35 million shares of worth about $33.58 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 87.64% during that period and on March 26, 2025 the price saw a gain of about 6.14%. Currently the company’s common shares owned by public are about 153.04M shares, out of which, 122.54M shares are available for trading.
Stock saw a price change of -0.20% in past 5 days and over the past one month there was a price change of -3.28%. Year-to-date (YTD), WVE shares are showing a performance of -19.00% which increased to 73.66% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.25 but also hit the highest price of $16.74 during that period. The average intraday trading volume for Wave Life Sciences Ltd shares is 930.46K. The stock is currently trading -1.01% below its 20-day simple moving average (SMA20), while that difference is down -7.60% for SMA50 and it goes to 2.73% higher than SMA200.
Wave Life Sciences Ltd (NASDAQ: WVE) currently have 153.04M outstanding shares and institutions hold larger chunk of about 79.46% of that.
The stock has a current market capitalization of $1.54B and its 3Y-monthly beta is at -1.05. It has posted earnings per share of -$0.79 in the same period. It has Quick Ratio of 2.89 while making debt-to-equity ratio of 0.12. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for WVE, volatility over the week remained 7.28% while standing at 7.65% over the month.
Stock’s fiscal year EPS is expected to drop by -36.07% while it is estimated to decrease by -2.76% in next year. EPS is likely to shrink at an annualized rate of 6.80% for next 5-years, compared to annual growth of 34.27% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Jefferies on February 25, 2025 offering a Buy rating for the stock and assigned a target price of $26 to it. Coverage by Raymond James stated Wave Life Sciences Ltd (WVE) stock as a Strong buy in their note to investors on October 16, 2024, suggesting a price target of $22 for the stock. On September 27, 2024, JP Morgan Resumed their recommendations, while on September 19, 2024, B. Riley Securities Initiated their ratings for the stock with a price target of $11. Stock get an Overweight rating from JP Morgan on September 09, 2024.
